Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial.

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial.

<h4>Background</h4>The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human...

Full description

Bibliographic Details
Main Authors: Piero Ruscitti, Francesco Masedu, Saverio Alvaro, Paolo Airò, Norma Battafarano, Luca Cantarini, Francesco Paolo Cantatore, Giorgio Carlino, Virginia D'Abrosca, Micol Frassi, Bruno Frediani, Daniela Iacono, Vasiliki Liakouli, Roberta Maggio, Rita Mulè, Ilenia Pantano, Immacolata Prevete, Luigi Sinigaglia, Marco Valenti, Ombretta Viapiana, Paola Cipriani, Roberto Giacomelli
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-09-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1002901

Internet

https://doi.org/10.1371/journal.pmed.1002901

Similar Items